Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Thursday 25 July, 2019

Winchester MD Ltd

Winchester Partner Biotti appoints Advisor

RNS Number : 6175G
Winchester MD Limited
25 July 2019
 

 

Winchester MD partner BIOTTI appoints Dr Alex Makriyannis - advisor to Pfizer, Biogen and BMS - to Champion cannabinoid pharmaceutical research and THC/CBD Edibles application mandates

 

LONDON, July 25th, 2019 - WINCHESTER MD LIMITED ("Winchester" or the "Company") is pleased to announce that Pfizer, Bristol-Myers Squibb, and Biogen Advisor, Dr. Alex Makriyannis, PhD, joins Biotii Technologies Corp. ("Biotii"), the Biosynthesis Cannabinoid Company in which the Company has a strategic shareholding; to Champion Cannabinoid Pharmaceutical Research and THC/CBD Edibles Application Mandates

 

Biotii has entered into a cannabinoid pharmaceutical advisory agreement (the "Agreement") with Pfizer, Bristol-Myers Squibb, and Biogen Advisor, Dr. Alexandros Makriyannis, PhD ("Dr. Makriyannis"). A professor of Chemistry and Chemical Biology in the Department of Medicinal Chemistry at Northeastern University, Dr. Makriyannis is credited with numerous scientific cannabinoid-centric achievements, including the discovery of cannabinoid receptor antagonists, as well as pioneering inmetabolically stable endocannabinoids.

 

Dr. Makriyannis will champion the Company's pursuit of biosynthesizing cannabinoids identical to those found in nature, with the objective of standardizing pharmacological effects within the human endocannabinoid system. Highly specialized knowledge of cannabinoid biochemistry, as well as the macro human endocannabinoid system equips Biotii with a first mover competitive advantage to economically scale its synthesized cannabinoid platform.

 

By 2020, Biotii intends to establish processes to efficiently mass-produce CBD/THC in quantities of hundreds of metric tonnes per annum, which boast:

·      Stable and consistent yields;

·      Pharmaceutical-grade purities; and,

·      The lowest production costs in the space.

·     

Biotii's scalable synthesizing process will enable the manufacturing of enigmatic cannabis compounds, as well as THC and CBD at materially lower costs when compared with conventional cultivation and extraction processes. Traditional cultivation of cannabis plants for the purpose of extracting cannabidiolic acid, THC and CBD is a time, labour and resource intensive endeavour that can result in depressed extraction yields of approximately 2.5 per cent.

 

Armed with a successful track record of generating cannabinoid centric intellectual property ("IP"), including the authoring of 37 related patents within the United States, Dr. Makriyannis will assist in guiding Biotii with their corporate mandate of securing a robust portfolio of defendable IP. Dr. Makriyannis is exclusively qualified to ensure Biotii's retains its competitive advantage as one of the first innovators to economically biosynthesize cannabinoids at industrial scale.

 

Underpinning his lifetime of achievements in academia and cannabis related research, including the design of cannabinoid receptor probes as early as 1995, Dr. Makriyannis was trained at the University of California, Berkeley, Tufts Medical School, as well as the Massachusetts Institute of Technology.

 

Dr. Makriyannis has lectured at over 110 institutions including preeminent, multinational pharmaceutical companies and academic centres such as Abbott Laboratories, the American Chemical Society, Harvard Medical School, Columbia University, and Yale. The Company's new advisor gives Biotii direct access to a vast network of global leaders within the cannabis research community. Dr. Makriyannis' previous advisory clientele includes:

·      Pfizer;

·      Bristol Myers;

·      Biogen Idec;

·      Nestle;

·      Glaxo Wellcome;

·      Genaissance Pharmaceuticals;

·      MAKScientific;

·      Forest Laboratories;

·      Arqule Pharmaceuticals; and,

·      Aileron Therapeutics.

 

Dr. Makriyannis' deep-seated comprehension of the human endocannabinoid system is further demonstrated by 430 published research papers validated within the peer reviewed scientific journal arena. Collectively the aforementioned research papers have generated over 15,360 additional citations.

Dr. Makriyannis asserted: "As the scientific community's global understanding of the human endocannabinoid system expands and social acceptance of cannabis increases, it is truly exciting to join Biotii in its pursuit of radical advancements within the biosynthesis of cannabinoids. Together we champion a long-term focus on discovering sustainable pharmaceutical applications for cannabis related medicines with the objective of improving patient outcomes."

 

Throughout his esteemed career, Dr. Makriyannis has secured non-dilutable funding in the form of US$4 million in research grants awarded by the U.S. National Institute of Health ("NIH"). Dr. Makriyannis' intricate knowledge of the scientific research grant model will provide Biotii with a coveted opportunity to pursue for non-diluted funding, thus augmenting the Companies operational and research runway. Recent NIH grants and previous industry funding awards, spearheaded by Dr. Makriyannis include:

·      Cannabinoid Receptor 2 Signaling;

·      Supplementation of Omega-3 Fatty Acids during Pregnancy;

·      Candidate Medications for Cannabis Addiction: FAAH Inhibitors;

·      Cannabinergic Medications for Methamphetamine Addiction;

·      Endocannabinoid Active Sites as Therapeutic Targets;

·      Cannabimimetic Ligands and Drugs;

·      Training Program in Medications Development for Drugs of Abuse;

·      Novel Medications for Cannabis Dependence;

·      Endo Pharmaceuticals CB2 Selective Agonists;

·      Glaxo Wellcome Design and Synthesis of Antineoplastic Alkyl Lysophospholipids;

·      Glaxo Wellcome Antineoplastic Ether Lipids Molecular Mechanisms of Action;

·      WHO World Health Organization Research Award; and,

·      Pfizer Central Research Development of Porcine Somatotropin Receptor Binding Assays.

 

Dr. John Harrold, Biotii's Chief Executive Officer and Co-Founder stated: "Professor Makriyannis has achieved global cannabis related research for more than three decades. In joining Biotii's scientific advisory board, Makriyannis offers not only his expertise of individual cannabinoid molecules, but also his knowledge of ligand receptor interactions within the human endocannabinoid system. By leveraging direct access to targeted intel on CB1 receptor and CB2 receptor interactions, … Biotii hopes to gain an additional competitive advantage in building the world's first scaled cannabinoid biosynthesis platform."

 

 "The important appoinment of Dr Makrlyannis gives Biotii's outstanding management team of professionals from Harvard and MIT a further competitive advantage by bringing his singular and great understanding of the human endocannabinoid system." said Faz Moshfeghi, CEO and Co-Founder of Winchester.

 

For more information, please visit www.winchestermd.com

 

On Behalf of the Board,

Faz Moshfeghi

CEO

[email protected]

 

About Winchester MD Limited

 

Winchester MD is a vertically integrated European cannabis company based out of London, UK. The Company was founded in 2018 with an initial focus on CBD Wellness through a revenue producing online retail superstore platform Hemp Elf www.hempelf.com. The Company offers a variety of CBD branded products through its on line superstore and continues to develop and market new products in the CBD Wellness category. In 2019 the Company has expanded into other verticals in the cannabis sector with the vision of becoming a global cannabis leader with cultivation, extraction, CBD wellness and research and development. 

 

This release has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000. Therefore this release has not been subject to the procedures and controls which would apply if they were made or approved as a financial promotion by an authorised person. This release is not intended to be a financial promotion or offer to the public and the Company is not making an invitation to invest into the share capital of the Company.

 

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or "occur". Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.

 

The Regulation Services Provider accepts no responsibility for the adequacy or accuracy of this release.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NRAEALXLAADNEFF

a d v e r t i s e m e n t